ArticleFrontiers in oncology2025
Primary liver cancer burden and its association with health development in the Western Pacific, 1990-2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Burden and epidemiological trends of alcohol use disorder and alcoholic liver disease in the Asia-Pacific region].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver cancer (LC) is a major public health challenge in the Western Pacific Region (WPR), characterized by etiological diversity and increasing burden from both infectious and noninfectious causes. This study aimed to assess the burden of primary LC and its association with health system development indicators across the WPR from 1990 to 2021. Methods: We conducted a secondary analysis using data from the Global Burden of Disease (GBD) Study 2021, covering 31 countries and territories in the WPR. LC burden was evaluated in terms of incidence, prevalence, mortality, and disability-adjusted life years (DALYs), stratified by sex, age, location, and five etiologies: hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol use, nonalcoholic steatohepatitis (NASH), and other causes. Associations with Human Resources for Health (HRH), Universal Health Coverage (UHC) index, and Sociodemographic Index (SDI) were examined using Spearman correlation and generalized linear models. Results: Between 1990 and 2021, age-standardized DALYs rates for LC in the WPR rose from 281.78 to 334.74 per 100,000 population (EAPC: 0.56%). Total incidence nearly doubled, with sharp increases in Mongolia, Australia, and China. HBV remained the leading cause, while burdens from alcohol use and NASH grew markedly. LC burden showed moderate to strong positive correlations with HRH, UHC, and SDI, especially for HCV- and NASH-related cases; HBV-related burden showed weak associations. Conclusions: Despite progress in viral hepatitis control, the LC burden continues to rise in the WPR. Integrated strategies targeting viral, metabolic, and alcohol-related causes are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.